Technology Development: Tailored Nano-Molecular Systems for New Modes of Reactivity
Technology Development: Tailored Nano-Molecular Systems for New Modes of Reactivity
批准号:
10401246
负责人:
TODD D KRAUSS
金额:
$18.71万
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
已结题
起止时间:
2021-06-01 至 2024-05-31
关键词:
AreaBindingBiologicalBirthCatalysisCharacteristicsChargeChemicalsChemistryComplexDevelopmentDiffuseDyesElectron TransportElectronsEnergy TransferFoundationsGenetic RecombinationGoalsGrantImageKineticsLigandsMolecularMolecular TargetOrganic SynthesisOutcomeOxidation-ReductionPharmaceutical PreparationsPhotonsProcessPropertyProtocols documentationQuantum DotsReactionReducing AgentsResearchScientistSemiconductorsSeriesSolar EnergySpace ExplorationsSurfaceSystemTestingTranslatingUniversitiesVisionWisconsinWorkbasecatalystcomputerized toolsdrug candidatedrug developmentdrug discoverydrug synthesisinnovationmaterials sciencenanonew technologynew therapeutic targetpreventprogramsquantum chemistryside effectsmall moleculetechnology developmenttooltwo-photon
中文摘要
尽管不断取得进展,候选药物的合成仍然是药物发现的限制因素。
商业现实意味着,需要太长时间才能获得的分子不会被制造或测试。光氧化还原
催化通过后期分子多样化迅速对这个问题产生了影响,这是一个很有希望的途径。
以最小的努力增加测试的化学空间。然而,可用的反应受到以下因素的限制
已确定的催化剂数量相对较少。需要具有新性质的催化剂,以使
新型光氧化还原反应。半导体量子点是一类很有前途的催化剂。
这不同于目前可用的任何一种。将多相催化剂的一些最佳性能与
由于均相催化剂的便利性,量子点具有令人印象深刻的、易于调整的光物理性质和
丰富的表面化学成分。光物理性质与支持配体的相对独立性
为反应发展提供了令人信服的新机遇。然而,量子点对药物的适应性
材料科学和有机合成之间的重叠很少,这减缓了发现的速度。这
该计划的长期目标是开发由量子点表面化学实现的新型化学。在……里面
提议的R21拨款,一个材料科学家团队(罗切斯特大学的克劳斯小组)和
合成化学家(威斯康星大学麦迪逊分校的韦克斯小组)将验证
QD光氧化还原催化剂,开发它们的使用协议,并与化学品供应商合作制造这些新的
商业上可以买到的工具。我们的指导性假设是量子点的表面化学可以
通过加速电子转移和预先安排催化剂或底物的新型光氧化还原反应。
这项提议的具体目的是:(1)使用支撑性和电活性配体来微调性质
QD光氧化还原催化剂与一系列已知反应的对比;(2)确定连接的最佳方法
QD表面的小分子催化剂促进多催化反应;(3)测试俄歇复合
可用于产生可能在有机合成中有用的强还原状态;以及(4)验证其用途
从量子点表面化学到模板大环化反应。这种方法是创新的,因为量子点是
从根本上不同于常用的光氧化还原催化剂,并将使反应活性不容易实现
使用小分子催化剂。拟议的研究具有重要意义,因为新工具将被广泛使用
可供选择,并可轻松整合到现有的光氧化还原研究计划中。
英文摘要
Despite continual advancements, the synthesis of drug candidates remains a limiting factor in drug discovery.
Commercial realities mean that molecules that take too long to access are not made or tested. Photoredox
catalysis has quickly made an impact on this problem via late-stage molecule diversification, a promising avenue
to increase the chemical space tested with minimal effort. However, the available reactions are limited by the
relatively small number of identified catalysts. There is a need for catalysts with new properties that will enable
new types of photoredox reactions. Semiconductor quantum dots (QDs) represent a promising class of catalysts
that are unlike any currently available. Combining some of the best properties of heterogeneous catalysts with
the convenience of homogeneous catalysts, QDs have impressive, easily tuned photophysical properties and a
rich surface chemistry. The relative independence of the photophysical properties from the supporting ligands
provides a compelling, new opportunities for reaction development. However, the adaptation of QDs to drug
discovery has been slowed by the poor overlap between the materials science and organic synthesis. This
program’s long-term goals are the development of new types of chemistry enabled by QD surface chemistry. In
the proposed R21 grant, a team of materials scientists (Krauss group at the University of Rochester) and
synthetic chemists (Weix group at the University of Wisconsin-Madison) will validate the exciting potential of
QD photoredox catalysts, develop protocols for their use, and work with chemical suppliers to make these new
tools commercially available. Our guiding hypothesis is that the surface chemistry of quantum dots can allow
new types of photoredox reactions by accelerating electron transfer and pre-arranging catalysts or substrates.
The specific aims of this proposal are to: (1) use supporting and electroactive ligands to fine-tune the properties
of QD photoredox catalysts against a suite of known reactions; (2) determine the best approach to attaching
small molecule catalysts to the QD surface to enhance multicatalytic reactions; (3) test if Auger recombination
can be used to generate strongly reducing states potentially useful in organic synthesis; and (4) validate the use
of QD surface chemistry to template macrocyclization reactions. The approach is innovative because QDs are
fundamentally different from commonly used photoredox catalysts and will enable reactivity not easily possible
with small molecule catalysts. The proposed research is significant because the new tools will be made widely
available and can be easily incorporated into established photoredox research programs.
期刊论文(2)
专著(0)
科研奖励(0)
会议论文
DOI:
10.1021/acscatal.3c01984
发表时间:
2023-06
期刊:
ACS catalysis
影响因子:
12.9
作者:
[Julianna M. Mouat;Jonas K. Widness;Daniel G. Enny;Mahilet T. Meidenbauer;Farwa Awan;Todd D. Krauss;D. Weix]
通讯作者:
Julianna M. Mouat;Jonas K. Widness;Daniel G. Enny;Mahilet T. Meidenbauer;Farwa Awan;Todd D. Krauss;D. Weix
Technology Development: Tailored Nano-Molecular Systems for New Modes of Reactivity
-
批准号:10193067
-
项目类别:
-
资助金额:$23.98万
-
财政年份:2021
-
负责人:TODD D KRAUSS
-
依托单位:
国内基金
海外基金
登录
查看更多内容
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
-
批准号:32170319
-
项目类别:面上项目
-
资助金额:58.00万元
-
批准年份:2021
-
负责人:董春海
-
依托单位:
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
-
批准号:--
-
项目类别:--
-
资助金额:58万元
-
批准年份:2021
-
负责人:董春海
-
依托单位:
ID1 (Inhibitor of DNA binding 1) 在口蹄疫病毒感染中作用机制的研究
-
批准号:31672538
-
项目类别:面上项目
-
资助金额:62.0万元
-
批准年份:2016
-
负责人:孙跃峰
-
依托单位:
番茄EIN3-binding F-box蛋白2超表达诱导单性结实和果实成熟异常的机制研究
-
批准号:31372080
-
项目类别:面上项目
-
资助金额:80.0万元
-
批准年份:2013
-
负责人:杨迎伍
-
依托单位:
P53 binding protein 1 调控乳腺癌进展转移及化疗敏感性的机制研究
-
批准号:81172529
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2011
-
负责人:杨其峰
-
依托单位:
DBP(Vitamin D Binding Protein)在多发性硬化中的作用和相关机制的蛋白质组学研究
-
批准号:81070952
-
项目类别:面上项目
-
资助金额:35.0万元
-
批准年份:2010
-
负责人:刘师莲
-
依托单位:
研究EB1(End-Binding protein 1)的癌基因特性及作用机制
-
批准号:30672361
-
项目类别:面上项目
-
资助金额:24.0万元
-
批准年份:2006
-
负责人:徐宁志
-
依托单位: